Hologic, Inc. (HOLX)
Market Cap | 19.14B |
Revenue (ttm) | 3.99B |
Net Income (ttm) | 701.50M |
Shares Out | 232.27M |
EPS (ttm) | 2.92 |
PE Ratio | 28.27 |
Forward PE | 19.23 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,371,458 |
Open | 82.09 |
Previous Close | 81.72 |
Day's Range | 81.87 - 82.65 |
52-Week Range | 64.02 - 84.67 |
Beta | 0.98 |
Analysts | Buy |
Price Target | 87.60 (+6.31%) |
Earnings Date | Nov 7, 2024 |
About HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis ass... [Read more]
Financial Performance
In 2023, Hologic's revenue was $4.03 billion, a decrease of -17.12% compared to the previous year's $4.86 billion. Earnings were $456.00 million, a decrease of -64.98%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $87.6, which is an increase of 6.31% from the latest price.
News
Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference.
Hologic CEO on earnings beat: our Covid work has 'turbocharged' diagnostics business
Stephen MacMillan, Hologic CEO, joins 'Money Movers' to discuss the company's earnings, how the company is encouraging women to get health screenings, and more.
Hologic Analysts Boost Their Forecasts After Q3 Results
Hologic, Inc. HOLX reported upbeat earnings for its third quarter, but issued soft guidance on Monday.
Hologic, Inc. (HOLX) Q3 2024 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX) Q3 2024 Earnings Conference Call July 29, 2024 4:30 AM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President & CEO Essex Mitchell - COO Karle...
Hologic quarterly profit rises on strong demand for its women's health products
Medical technology company Hologic reported a higher third-quarter profit on Monday, driven by strong demand for its diagnostics and breast health products, but forecast revenue for the current quarte...
Hologic Announces Financial Results for Third Quarter of Fiscal 2024
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2024.
Hologic Completes Acquisition of Endomagnetics Ltd
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #breastcancersurgery--Hologic Completes Acquisition of Endomagnetics Ltd.
72 Million American Women Have Skipped or Delayed Vital Screenings
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #HGWHI--72 Million American Women Have Skipped or Delayed Vital Screenings.
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2024 on Monday, July 29, 2024
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Third Quarter of Fiscal 2024 on Monday, July 29, 2024.
Women's Health-Focused Hologic Has Significant Capacity For Expansion Via M&A, Bullish Analyst Says
Stephens initiated coverage on Hologic Inc HOLX, citing it as a major player in women's health, known for its consistent revenue growth, strong free cash flow, and attractive profit margins, is well-p...
Hologic CEO breaks down AI involvement in healthcare
Steve MacMillan, Hologic CEO, joins 'Squawk on the Street' to discuss how Hologic is installing AI into its products, how the company innovates on its products, and what specific problems are being so...
FDA classifies recall of Hologic's implants for soft tissue as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Hologic's devices that are implanted in soft tissue such as breast tissue as "most serious".
Hologic to Webcast Presentations at Upcoming Investor Conferences
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentations at Upcoming Investor Conferences.
Hologic: Women's Health Play Looks Healthier Itself
Hologic's women's health business benefited from the pandemic but is now facing headwinds that will end in 2024. The company has a strong balance sheet, solid track record, and reasonable valuation, m...
Hologic, Inc. (HOLX) Q2 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:24 PM ET Hologic, Inc. (NASDAQ:HOLX) Q2 2024 Earnings Conference Call May 2, 2024 16:30 ET Company Participants Ryan Simon - Vice President, Investor Relations Ste...
Hologic Announces Financial Results for Second Quarter of Fiscal 2024
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for the Second Quarter of Fiscal 2024.
Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #acquisition--Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company.
Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and Hologic, Inc. (Nasdaq: HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The...
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024.
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #JNCCN--Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors .
FDA warns of potential risk of complications with use of Hologic's devices
The U.S. Food and Drug Administration on Tuesday warned patients and healthcare providers about the potential risk of serious complications arising from the use of Hologic's devices that are implanted...
Hologic to Unveil Groundbreaking AI Research at ECR 2024
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Hologic to Unveil Groundbreaking AI Research at ECR 2024.
Hologic: Prospects For Growth As Headwinds Disappear
Hologic aims to elevate women's health globally, with diagnostics making up nearly half of sales. The company experienced a boom in COVID diagnostics sales in 2020 and 2021, creating headwinds thereaf...
Hologic CEO on Q1 earnings, AI in health care
Steve MacMillan, Hologic CE, joins 'Money Movers' to discuss the company's new AI cervical screening system, Hologic's quarterly earnings results, and more.
Hologic, Inc. (HOLX) Q1 2024 Results - Earnings Call Transcript
Hologic, Inc. (HOLX) Q1 2024 Results - Earnings Call Transcript